Overview
Virtual Event
Click Here to View the Program in Japanese
Click Here to View the Program in English
Taking the theme “Beyond Innovation”, the Japan Annual Meeting 2020 will bring together academia, regulators, industry professionals, and patients from across the world to exchange information and discuss the latest trends in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products.
This is the largest event in the DIA Japan annual calendar and features more than 60 sessions on topics ranging from Risk Management, Patient Engagement and Pharmacovigilance to the 30th anniversary of ICH, the future of Healthcare, and the COVID-19 pandemic. Our hugely popular PMDA Town Hall DIAmond session also makes a return to the program.
This year’s Meeting will be held entirely online through a fully integrated platform offering live and on-demand content, live Q&A sessions with speakers, group and 1-2-1 networking opportunities and much more! Breaking walls and boundaries, the virtual platform will enable you to join the event from wherever you may be and to connect with fellow professionals from across the world.
We look forward to seeing you there!
Event Concept
Amidst the backdrop of the fourth industrial revolution, recent years have seen the launch of initiatives related to various innovations that will create new value and bring about major changes for our society. These innovations are an outcome of the creation and application of new techniques and technologies exemplified by the use of artificial intelligence, big data, and medical and genomic information in various fields, including research and development and lifecycle management of medical devices.
Currently, the global COVID-19 pandemic has reaffirmed the importance of the role played by medical products in providing treatment and medications to support the health and safety of people everywhere. At the same time however, efforts to take on new challenges aimed at creating new innovations that break away from conventional wisdom are underway around the globe.
As society adapts to the ongoing presence of COVID-19, it is becoming more and more important that we actively seek to learn the latest technologies and initiatives that will underpin various innovations, consider how our jobs will change and how we should reimagine those jobs moving forward, and develop the skills and mindset that will allow us to respond and adapt to these major changes. But we should also ask ourselves: do the new values and changes brought about through innovation really play a role in improving the health and welfare of patients? Perhaps it’s time for each and every stakeholder to return to the starting line and chart a path forward together.
With the theme of “Beyond Innovation”, the 17th DIA Japan Annual Meeting offers programs that are based on session proposals submitted by DIA members in an open call for submissions. We hope these will be attractive and informative for participants. In addition to a commemorative address marking 30 years of ICH activities, there will be lectures covering patient-focused drug development, overcoming drug-induced illnesses, international contributions to drug development, and the future of healthcare. Additionally, the hugely popular PMDA town hall will once again be held this year. We hope this event serves to provide a space where stakeholders—including patients—from industry, government, and academia can learn the latest information and enjoy interactive discussions.
Program Committee
-
Yuji Kumagai, MD, PhD • Professor, Clinical Research Center
Kitasato University Hospital, Japan -
Keiichi Inaizumi, MSc • Japan Clinical Project Manager, Clinical Operations and Compliance 1
Pfizer R&D Japan, Japan -
Taro Amagasaki, PhD • Head, Analytics Japan
Novartis Pharma K.K., Japan -
Nobuyuki Hanamura, PhD, MBA • Senior Director, Clinical Development Strategy & Solutions
Japan -
Toshiko Ishibashi, PhD, RN • Associate Director,Oncology Medical Science Department
Daiichi Sankyo Co., Ltd., Japan -
Kazuhiko Ishida, MSc, RPh • Director, Risk Management, Pharmacovigilance
Astellas Pharma Inc., Japan -
Yayoi Kitawaki, MS • Senior Japan Program Head, Oncology Development Unit, Japan Development
Novartis Pharma K.K., Japan -
Yoshiko Komuro, PhD • Inspection Director in Office of Non-clinical and Clinical Compliance
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Takashi Moriya, PhD, MBA • Director
Janssen Pharmaceutical K.K., Japan -
Sumimasa Nagai, MD, PhD • Senior Assistant Professor, Translational Research Center
The University of Tokyo Hospital, Japan -
Shinichi Nishiuma, MD • Head of Oncology Medical Science, Japan medical
Bristol-Myers Squibb K.K., Japan -
Mika Ogasawara • Quality Lead, Biometrics and Data Management
Pfizer R&D Japan, Japan -
Goshi Ozawa, MS • Exective officer, RWD dept.
Real World Data Co., Japan -
Keiko Tsumori • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Junichi Nishino, MSc, RPh • Director, Medical Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Hironobu Saito, PhD • Corporate Officer /Head of Medical Affairs Div.
Daiichi Sankyo Co., Ltd., Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Takashi Sato, MSc, PMP • Manager, Project Management Group, R&D Planning Department
Kyowa Kirin Co., Ltd., Japan -
Atsushi Tsukamoto, PhD, MSc •
Daiichi Sankyo Company, Limited, Japan